Core Viewpoint - uniQure N.V. is set to report its fourth quarter and full year 2025 financial results on March 2, 2026, highlighting its ongoing commitment to advancing gene therapies for severe medical conditions [1]. Group 1: Financial Reporting - The financial results will be announced before market open on March 2, 2026, followed by a conference call at 8:00 a.m. ET [1]. - The event will be accessible via webcast on uniQure's website, with a replay available for 90 days post-event [2]. Group 2: Company Overview - uniQure is recognized for its pioneering work in gene therapy, particularly for hemophilia B, marking a significant milestone in genomic medicine [3]. - The company is advancing a pipeline of proprietary gene therapies targeting conditions such as Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease, among others [3].

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important  April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s Huntington’s disease gene therapy drug.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.c ...

Faruqi, LLP also encourages anyone with information regarding uniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the uniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired uniQure securities between September 24, 2025 and October 31, 2025, both dates ...

LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises UniQure N.V., (“uniQure” or the "Company") (NASDAQ: QURE) investors of a class action on behalf of investors that bought securities between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). uniQure investors have until April 13, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal righ ...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recov ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Far ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The uniQure Class Action Lawsuit: Do you, or did you, own shares of uniQure N.V. (QURE)?Did you purchase your shares between September 24, 2025 and October 31, 2025, inclusive?Did you lose money in y ...

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging material misstatements regarding the company's Huntington's disease gene therapy drug [1]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for the lawsuit is defined as September 24, 2025, to October 31, 2025, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. - The allegations include misleading statements about the Phase I/II clinical trials of uniQure's leading drug candidate, AMT-130, and the timeline for its Biologics License Application (BLA) submission to the FDA [1]. Group 2: Allegations Against uniQure - The complaint claims that uniQure misrepresented the approval status of the Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA timeline due to the need for additional studies [1]. - It is alleged that the defendants failed to disclose material adverse facts about uniQure's business and operations, leading to a lack of reasonable basis for their statements regarding the company's prospects [1]. Group 3: Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be a lead plaintiff by the specified deadline [1]. - The lead plaintiff process allows investors to represent the class in directing the litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1].